Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Rutgers Cancer Institute researchers awarded $2.3 million in American Cancer Society grants

More than $2.3 million in Research Scholar Grants from the American Cancer Society have been awarded to three Rutgers Cancer Institute of New Jersey researchers to examine cell metabolism and tumor formation in forms of breast cancer, lung cancer and leukemia.

19 Nov 2019

Surgery can improve survival rate for oldest patients with early stage lung cancer

Many patients with early stage lung cancer who are age 90 years and older do not receive treatment; however, surgery in this nonagenarian population should be considered because it could significantly increase the chances for 5-year survival, according to research published online today in The Annals of Thoracic Surgery.

19 Nov 2019

Cancer patients with RA treated with immune checkpoint inhibitors likely to experience a flare

A new study found that cancer patients with a pre-existing autoimmune disease receiving immune checkpoint inhibitors as treatment are likely to experience a flare.

11 Nov 2019

Study: Pleural effusions are linked with NSCLC and malignant mesothelioma

Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system.

6 Nov 2019

HIMC at Mount Sinai to evaluate therapeutic effects of novel cancer immunotherapy

The Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi.

5 Nov 2019

Research finds disparities in receiving recommended treatment for lung cancer

Only about 6 in 10 lung cancer patients in the United States receive the minimal lung cancer treatments recommended by the National Comprehensive Cancer Network guidelines, according to new research published online in the Annals of the American Thoracic Society.

30 Oct 2019

Disrupting key immune regulator boosts anti-tumor immunity, enables cancer clearance

The immune system must strike an exquisite balance between vanquishing infections and cancer, while at the same time restraining its activity to avoid inadvertently attacking the body's healthy tissues and organs.

23 Oct 2019

Dartmouth scientist awarded grant to build new AI technologies for lung cancer management

Lung cancer is the second most common type of cancer and leading cause of cancer death in men and women, with non-small cell lung cancer (NSCLC) accounting for up to 90% of cases. Somatic mutations heavily impact the sensitivity of NSCLC patients to various drug treatments, and are critical for choosing the most effective targeted therapies for this cancer.

23 Oct 2019

CRISPR helps find difficult to detect cancer cells

Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.

15 Oct 2019

Combination of two drugs disrupts cancer cells' ability to survive DNA damage, study finds

In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine have identified a new pathway that leads to the destruction of cancer cells.

14 Oct 2019

New algorithm hand-picks which cancer mutations are promising targets for immunotherapy

As tumor cells multiply, they often spawn tens of thousands of genetic mutations. Figuring out which ones are the most promising to target with immunotherapy is like finding a few needles in a haystack.

9 Oct 2019

Lung cancer may soon be picked up by a blood test

A study presented at the ESMO Congress 2019 has revealed that a blood test may soon be able to pick up circulating tumor DNA to help avoid invasive tissue biopsies in lung cancer patients.

30 Sep 2019

Higher levels of genetic mutations linked to improved outcomes in lung cancer patients

According to new findings by Yale Cancer Center scientists, higher levels of genetic mutations in a tumor biopsy are linked to improved clinical outcomes in patients using pembrolizumab (Keytruda) to treat non-small cell lung cancer (NSCLC).

27 Sep 2019

Combination therapy may offer new therapeutic avenue for previously-treated NSCLC and kidney cancer patients

Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer and kidney cancer.

26 Sep 2019

Adding radiation after immunotherapy increases PFS for some patients with metastatic NSCLC

Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer, increasing progression-free survival.

26 Sep 2019

Tasmanian devil study may give clues to how cancers evade the immune system

A cluster of interacting proteins that are active in both human cancers and Tasmanian devil facial tumors, may give clues to how cancers evade the immune system, according to a study part-funded by Cancer Research UK and published in Cancer Cell today.

26 Sep 2019

Investigational drug may offer new treatment option for patients with lung and kidney cancer

26 Sep 2019

Reactivating ‘tumor suppressor’ genes could offer new therapeutic approach for cancer

Scientists have developed a method which is able to switch ‘tumor suppressor’ genes back on after they have been silenced by cancer cells.

25 Sep 2019

Pembrolizumab provides added benefit for subpopulations of patients with metastatic NSCLC

In early July, the German Institute for Quality and Efficiency in Health Care conducted two early benefit assessments to investigate whether certain drug combinations with pembrolizumab have advantages in comparison with the respective appropriate comparator therapy for patients with metastatic squamous or non-squamous non-small cell lung cancer.

20 Sep 2019

Scientists identify pathway for treatment-resistant lung cancer

A big way chemotherapy works is by prompting cancer cells to commit suicide, and scientists have found a pathway the most common lung cancer walks to avoid death.

20 Sep 2019

Small Cell Lung Cancer News and Research

Rutgers Cancer Institute researchers awarded $2.3 million in American Cancer Society grants

Surgery can improve survival rate for oldest patients with early stage lung cancer

Cancer patients with RA treated with immune checkpoint inhibitors likely to experience a flare

Study: Pleural effusions are linked with NSCLC and malignant mesothelioma

HIMC at Mount Sinai to evaluate therapeutic effects of novel cancer immunotherapy

Research finds disparities in receiving recommended treatment for lung cancer

Disrupting key immune regulator boosts anti-tumor immunity, enables cancer clearance

Dartmouth scientist awarded grant to build new AI technologies for lung cancer management

CRISPR helps find difficult to detect cancer cells

Combination of two drugs disrupts cancer cells' ability to survive DNA damage, study finds

New algorithm hand-picks which cancer mutations are promising targets for immunotherapy

Lung cancer may soon be picked up by a blood test

Higher levels of genetic mutations linked to improved outcomes in lung cancer patients

Combination therapy may offer new therapeutic avenue for previously-treated NSCLC and kidney cancer patients

Adding radiation after immunotherapy increases PFS for some patients with metastatic NSCLC

Tasmanian devil study may give clues to how cancers evade the immune system

Investigational drug may offer new treatment option for patients with lung and kidney cancer

Reactivating ‘tumor suppressor’ genes could offer new therapeutic approach for cancer

Pembrolizumab provides added benefit for subpopulations of patients with metastatic NSCLC

Scientists identify pathway for treatment-resistant lung cancer

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News